Table 2.
Subgroup analyses by molecular markers for colon cancer-specific mortality comparing high to low levels of physical activity
| Events/ N | MET-hours / week ≥ 18 vs MET-hours / week < 18 Hazard ratio † (95% CI) |
P interaction |
|
|---|---|---|---|
| All patients with tumor blocks * | 50/484 | 0.64 (0.33-1.23) | |
| FASN | 0.77 | ||
| Negative | 41/390 | 0.61 (0.30-1.25) | |
| Positive | 4/66 | 0.95 (0.11-8.06) | |
| K-ras | 0.59 | ||
| Wildtype | 25/284 | 0.71 (0.28-1.82) | |
| Mutation | 22/169 | 0.42 (0.15-1.18) | |
| p53 | 0.58 | ||
| Negative | 20/276 | 0.46 (0.16-1.35) | |
| Positive | 26/192 | 0.64 (0.26-1.59) | |
| p21 | 0.19 | ||
| Lost | 37/360 | 0.87 (0.42-1.81) | |
| Expressed | 8/90 | 0.10 (0.01-0.98) | |
| p27 | 0.03 | ||
| Lost | 17/195 | 1.40 (0.41-4.72) | |
| Expressed | 28/251 | 0.32 (0.12 – 0.85) | |
| PI3KCA | 0.96 | ||
| Wildtype | 33/340 | 0.59 (0.26-1.33) | |
| Mutation | 7/69 | 1.25 (0.25-6.40) | |
Abbreviations: MET = metabolic equivalent hours; N = total number of patients; CI = confidence interval
*
Block cohort represents subjects who had tumor blocks available, post diagnosis physical activity data and stages I-III at diagnosis. The number of patients varies for each marker since some samples were indeterminant for certain markers.
†
Adjusted for age, gender, stage, year of diagnosis, histology grade, body mass index, time of physical activity assessment